Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Sulfadoxine-pyrimethamine (SP) is the current first-line treatment for uncomplicated malaria in Malawi. The malaria parasite P. falciparum has developed resistance to this drug so that the drug is much less effective than in previous years. This study was developed and conducted in collaboration with the National Malaria Control Programme of Malawi to assess the efficacy of four antimalarial drug combinations to provide evidence to assist the Malawian Ministry of Health in identifying and implementing as policy the next first-line antimalarial for uncomplicated malaria in Malawi. In an open, randomized trial in children under five years of age, four drug combinations, all of which are licensed in Malawi, are being assessed: amodiaquine plus sulfadoxine-pyrimethamine (AQ-SP), amodiaquine plus artesunate (AQ-Art), chlorproguanil-dapsone plus artesunate (CD-Art) and lumefantrine-artemether (LA). SP is also included as a fifth arm of the study for current data on its efficacy. Data on side effects of the drugs will also be collected. The results of this study will provide some of the information necessary to guide the Malawi National Malaria Control Program in selecting its next first antimalarial treatment for uncomplicated malaria. The study adheres to the World Health Organization's 2003 standardized protocol for assessing antimalarial drug efficacy.
Condition or disease
Drug: sulfadoxine-pyrimethamineDrug: amodiaquine plus sulfadoxine-pyrimethamineDrug: amodiaquine plus artesunateDrug: chlorproguanil-dapsone plus artesunateDrug: lumefantrine-artemether
An Open Randomised Trial of the Efficacy of Sulfadoxine-Pyrimethamine (SP), Amodiaquine + SP (AQ-SP), AQ + Artesunate (AQ-Art), Chlorproguanil-Dapsone + Art (CD-Art), and Lumefantrine-Artemether (LA) for Uncomplicated Malaria in Malawi
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
6 Months to 59 Months (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Children age 6 - 59 months
Axillary temperature ≥ 37.5 °C
Monoinfection with P. falciparum
Parasitaemia between 2000 - 200000 parasites/µl
Haemoglobin concentration (finger-prick blood sample by HemoCue) > 7g/dl
Consent by the patient's adult guardian
Residence in the locality and willingness to attend for scheduled visits
prostration (inability to sit/stand/suck/drink)
respiratory distress or breathlessness
persistent vomiting (cannot keep down liquids)
evidence of a diagnosis other than malaria on physical examination
presence of mixed infection
presence of severe malnutrition (as evidenced by symmetrical oedema involving at least the feet, light hair color, or cachexia)
contraindications to the antimalarial drugs used, especially history of allergy
history of receiving a drug with antimalarial activity in the week prior to enrollment